JPML To Consolidate Zantac Lawsuits
JPML To Consolidate Zantac Lawsuits
Introduction
The U.S Judicial Panel on Multidistrict Litigation (JPML) has decided to consolidate and centralize the growing number of Zantac lawsuits before U.S. District Judge Robin L. Rosenberg in Florida for coordinated discovery and pretrial proceedings.
There are more than 140 product liability and class action lawsuits pending in two dozen different federal court districts nationwide. Each lawsuit has similar allegations, stating that the active ingredient in Zantac, ranitidine, produces high levels of the known human carcinogen Nitrosodimethylamine (NDMA). Plaintiffs claimed that exposure to the chemical for extended periods of time caused them to develop bladder cancer, kidney cancer, colorectal cancer, stomach cancer, and other forms of cancer along the digestive tract.
A citizen’s petition was filed with the FDA in September 2019, which resulted in the recall of Zantac indicating the drug should be considered a human carcinogen. In November, a group of plaintiffs filed a motion to centralize lawsuits as part of a federal MDL. Following the motion, the JPML issued a transfer order last week for consolidation.
Latest News
Teen E-cigarette Use Hits 10-Year Low
Federal officials report a significant decline in teen vaping rates in the U.S., with about half a million fewer middle and high school…
Baltimore, Walgreens Reach Opioid Settlement Totaling $402.5m
The City of Baltimore has reached a settlement with Walgreens over its involvement in the opioid crisis, marking the…